Hua Zhang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9590884/publications.pdf

Version: 2024-02-01

		393982	344852
41	2,248	19	36
papers	citations	h-index	g-index

42	42	42	4649
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discovery, 2018, 8, 216-233.	7.7	503
2	Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery, 2018, 8, 196-215.	7.7	392
3	Clinical Characteristics and Outcomes of COVID-19â€“Infected Cancer Patients: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2021, 113, 371-380.	3.0	153
4	CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell, 2020, 37, 37-54.e9.	7.7	138
5	In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma. Cancer Discovery, 2020, 10, 270-287.	7.7	129
6	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Journal of Thoracic Oncology, 2020, 15, 520-540.	0.5	119
7	Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nature Medicine, 2011, 17, 715-719.	15.2	118
8	The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes and Development, 2019, 33, 1718-1738.	2.7	65
9	Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. OncoImmunology, 2018, 7, e1396403.	2.1	60
10	Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. Clinical Cancer Research, 2020, 26, 3431-3442.	3.2	41
11	NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model. Cancer Research, 2018, 78, 3709-3717.	0.4	38
12	Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. Science Advances, 2021, 7, .	4.7	38
13	The dual function of KSR1: a pseudokinase and beyond. Biochemical Society Transactions, 2013, 41, 1078-1082.	1.6	37
14	The role of pseudokinases in cancer. Cellular Signalling, 2012, 24, 1173-1184.	1.7	32
15	The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated Induction of Integrin Î²1. Science Signaling, 2014, 7, ra58.	1.6	32
16	Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. British Journal of Cancer, 2019, 120, 512-521.	2.9	31
17	TargetingHER2Exon 20 Insertionâ€“Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. Cancer Research, 2021, 81, 5311-5324.	0.4	31
18	Recent advances in preclinical models for lung squamous cell carcinoma. Oncogene, 2021, 40, 2817-2829.	2.6	26

#	Article	IF	Citations
19	LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer. Cell Reports, 2015, 12, 837-849.	2.9	21
20	ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation. Oncotarget, 2016, 7, 27599-27612.	0.8	21
21	Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics. Molecular and Cellular Proteomics, 2015, 14, 2479-2492.	2.5	17
22	Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2020, 80, 3556-3567.	0.4	17
23	Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in nonâ€“small cell lung cancer. Science Advances, 2022, 8, eabi9533.	4.7	16
24	Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours. Neuroendocrinology, 2021, 111, 465-474.	1.2	15
25	Therapeutic targeting of the mevalonateâ€“geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer. Nature Cancer, 2022, 3, 614-628.	5.7	14
26	Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury. Cell Reports Medicine, 2020, 1, 100145.	3.3	12
27	Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer. Breast Cancer Research and Treatment, 2015, 151, 555-568.	1.1	10
28	Shining a light on metabolic vulnerabilities in non-small cell lung cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188462.	3.3	9
29	Strategies in functional proteomics: Unveiling the pathways to precision oncology. Cancer Letters, 2016, 382, 86-94.	3.2	7
30	DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome. Clinical Cancer Research, 2022, 28, 3824-3835.	3.2	6
31	Broader implications of SILAC-based proteomics for dissecting signaling dynamics in cancer. Expert Review of Proteomics, 2014, 11, 713-731.	1.3	5
32	Targeting lemurs against cancer metastasis. Oncotarget, 2014, 5, 5192-5193.	0.8	4
33	Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis. National Science Review, 2022, 9, .	4.6	4
34	Proteome-wide dataset supporting functional study of tyrosine kinases in breast cancer. Data in Brief, 2016, 7, 740-746.	0.5	3
35	Programmed cell death (PD-1) ligands expression in gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs): relationship with angiogenesis and clinical outcome.. Journal of Clinical Oncology, 2016, 34, e15658-e15658.	0.8	3
36	Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments. Oncotarget, 2018, 9, 12805-12811.	0.8	2

#	Article	IF	Citations
37	Response to Cottu, Bozec, Basse, and Paoletti. Journal of the National Cancer Institute, 2021, 113, 344-345.	3.0	0
38	Response to Alpert and Taioli. Journal of the National Cancer Institute, 2021, 113, 503-504.	3.0	0
39	Response to Huang, Rivero-Hinojosa, Ma, et al. Journal of the National Cancer Institute, 2021, 113, 1111-1112.	3.0	0
40	The many-faced KSR1: a tumor suppressor in breast cancer. Oncoscience, 2015, 2, 669-670.	0.9	0
41	Abstract 185: Role of phosphorylation in Lmtk3 activation and its contribution in breast cancer progression. , 2016, , .		0